Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2020

View Archived Issues

Cholera toxin can subvert inflammation

Chip predicts intestinal drug metabolism

Phase I study of HBV candidate ZM-H1505R now recruiting

Phase IIb trial approved to evaluate SUBA-Itraconazole in prostate cancer

China NMPA accepts IND filing for TST-001 for solid tumors

FAM222A raises the risk of Alzheimer's disease

Master clock gene keeps macrophages asleep

Efficacy of siderophore-antibiotic conjugates in new mouse models of iron overload and depletion

Biogen presents new MAP3K5 inhibitors

Kinnate Biopharma describes CDK inhibitors

PTC Therapeutics discloses heteroaryl compounds for Huntington's disease

Incyte identifies PI3Kgamma inhibitors

Leo Pharma discovers JAK1 inhibitors

AKCEA-APOCIII-LRx meets primary endpoint in phase II hypertriglyceridemia trial

FDA clears IND for CYNK-001 in GBM

FDA clears IND application for HEALEY ALS platform trial

DIRC3 acts as a tumor suppressor in melanoma

Nubeqa approved in Japan for nonmetastatic castration-resistant prostate cancer

China's NMPA clears ASC-22 to begin trials for HBV in China

Altimmune demonstrates systemic antitumor activity with ALT-702 in preclinical study

Japanese approval of Dinagest for dysmenorrhea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...